Moderna will present late-breaking oral presentations on revaccination data for both mRNA-1010, its investigational seasonal influenza vaccine, and for mRESVIA
- Moderna's presentation, "Sequential administration of an mRNA-based seasonal influenza vaccine in older adults," details an exploratory, post-hoc analysis assessing the safety and immunogenicity of mRNA-1010 in adults 50 years and older following prior seasonal influenza vaccination with mRNA-1010 or a licensed egg-based influenza vaccine. The analysis was conducted among participants in the pivotal Phase 3 mRNA-1010 study (P304) who previously participated in another Phase 3 mRNA-1010 study (P302 or P303), in which participants received a single dose of mRNA-1010 or a licensed egg-based comparator. With a median time between vaccination of 23 months, day 29 hemagglutination inhibition geometric mean fold rises for all three WHO-recommended influenza strains (A/H1N1, A/H3N2, B/Victoria) were similar in participants who received mRNA-1010 in P304, regardless of prior study vaccination assignment, and numerically higher compared to participants who received a licensed egg-based comparator in P304. Additionally, there were no increases in solicited adverse reactions or new safety concerns observed with sequential mRNA-1010 vaccination.
- mRNA-1010 has been accepted for review in the United States, Europe, Canada and Australia, with further submissions planned in 2026. Moderna expects the first potential approvals for mRNA-1010 in 2026, subject to ongoing regulatory reviews.